0001178913-16-006659.txt : 20161013 0001178913-16-006659.hdr.sgml : 20161013 20161013081144 ACCESSION NUMBER: 0001178913-16-006659 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20161013 FILED AS OF DATE: 20161013 DATE AS OF CHANGE: 20161013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Check-Cap Ltd CENTRAL INDEX KEY: 0001610590 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36848 FILM NUMBER: 161934085 BUSINESS ADDRESS: STREET 1: ABBA HUSHI AVENUE P.O. BOX 1271 CITY: ISFIYA STATE: L3 ZIP: 30090 BUSINESS PHONE: 972-4-8303400 MAIL ADDRESS: STREET 1: ABBA HUSHI AVENUE P.O. BOX 1271 CITY: ISFIYA STATE: L3 ZIP: 30090 6-K 1 zk1619084.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For October 2016

Commission File No. 001-36848
 
Check-Cap Ltd.
Check-Cap Building
Abba Hushi Avenue
P.O. Box 1271
Isfiya, 30090
Mount Carmel, Israel
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒    Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes ☐    No ☒
 
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-___

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statement File No. 333-203384.


On October 13, 2016, Check-Cap Ltd. (the “Company”) announced upcoming presentations evaluating the Company's ingestible capsule for preparation-free, colorectal cancer screening.
 
Presentations will take place at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 14-19, in Las Vegas and the United European Gastroenterology Week (UEG) taking place October 15-19, in Vienna:
 
·
(Video Abstract #V9): "A Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening", Seth A. Gross, M.D., Associate Professor and Chief of Gastroenterology at Tisch Hospital, NYU Langone Medical Center; Monday Oct. 17, 4:45 p.m. PT – 6:00 p.m. PT; Venetian Ballroom D. Dr. Seth A. Gross is a member of Check-Cap's Scientific Advisors.
 
·
(Poster # P0208): "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening: Correlation between Capsule and Colonoscopic Clinical Findings", Nadir Arber, M.D., Director of the Integrated Cancer Prevention Center (ICPC) at Tel Aviv Sourasky Medical Center; Monday Oct. 17, 12:30 p.m. CET – 1:30 p.m. CET; Hall X5: Terminal 2. Prof. Arber is a member of Check-Cap's Scientific Advisors, provides consulting services to the Company as a medical director, and a leading investigator in its multicenter clinical study which is held at Tel Aviv Sourasky Medical Center and other sites.
 
A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference herein.
 
Exhibits

99.1
Press Release , dated October 13, 2016.
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Check-Cap Ltd.
  
       
 
By:
/s/ Lior Torem  
    Name: Lior Torem  
    Title: Chief Financial Officer      
       
Dated: October 13, 2016
 
 EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1

Exhibit 99.1
 

Check-Cap Announces Upcoming Presentations Evaluating Preparation-Free Colorectal Cancer Screening Capsule
 
- Presentations to take place at the American College of Gastroenterology Annual Scientific Meeting and the United European Gastroenterology Week -
 
ISFIYA, Israel, Oct. 13, 2016 /PRNewswire/ -- Check-Cap Ltd. (Nasdaq:  CHEK, CHEKW), a clinical stage medical diagnostics company, today announced upcoming presentations evaluating the Company's ingestible capsule for preparation-free, colorectal cancer screening.
 
Presentations will take place at the American College of Gastroenterology (ACG) Annual Scientific Meeting taking place October 14-19, in Las Vegas and the United European Gastroenterology Week (UEG) taking place October 15-19, in Vienna:
 
·
(Video Abstract #V9): "A Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening", Seth A. Gross, M.D., Associate Professor and Chief of Gastroenterology at Tisch Hospital, NYU Langone Medical Center; Monday Oct. 17, 4:45 p.m. PT – 6:00 p.m. PT; Venetian Ballroom D.
 
·
(Poster # P0208): "A Novel Preparation-Free X-Ray Imaging Capsule for Colon Cancer Screening: Correlation between Capsule and Colonoscopic Clinical Findings", Nadir Arber, M.D., Director of the Integrated Cancer Prevention Center (ICPC) at Tel Aviv Sourasky Medical Center; Monday Oct. 17, 12:30 p.m. CET – 1:30 p.m. CET; Hall X5: Terminal 2
 
About Check-Cap
 
Check-Cap is a clinical-stage medical diagnostics company developing the world's first ingestible capsule system for preparation-free, less-invasive colorectal cancer screening.
 
The capsule utilizes innovative ultra-low dose X-ray and wireless communication technologies to scan the inside of the colon as it moves naturally, while the patient follows his or her normal daily routine.   After passage, the system generates a 3D map of the inner surface of the colon which enables detection of polyps and cancer.  Designed to increase the willingness of individuals to participate in recommended colorectal cancer screening, the Check-Cap system addresses many frequently-cited barriers, including laxative bowel preparation, invasiveness, and sedation. The Check-Cap system is currently not cleared for marketing in any jurisdiction.
 
Legal Notice Regarding Forward-Looking Statements
 
This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
 
CONTACT:
 
Investors
David Carey
Lazar Partners Ltd.
212-867-1768
dcarey@lazarpartners.com
 
Media
Erich Sandoval
Lazar Partners Ltd.
917-497-2867
esandoval@lazarpartners.com
 
SOURCE Check-Cap Ltd.